Long-term nicotine replacement therapy: Cancer risk in context

Cancer Prevention Research

Volumn 4, Issue 11, 2011, Pages 1719-1723

  Shields, Peter G ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; NICOTINE; NITROSAMINE; NITROSONORNICOTINE;

CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CARDIOVASCULAR DISEASE; DISEASE COURSE; FOLLOW UP; HUMAN; LONG TERM CARE; LUNG CANCER; META ANALYSIS (TOPIC); METASTASIS; MOUTH CANCER; NICOTINE REPLACEMENT THERAPY; NONHUMAN; PANCREAS CANCER; PATIENT SAFETY; PRIORITY JOURNAL; RELAPSE; REVIEW; SMOKELESS TOBACCO; SMOKING CESSATION; THERAPY EFFECT; TOBACCO DEPENDENCE; TREATMENT DURATION; TUMOR GROWTH;

ADENOCARCINOMA; ADENOMA; ANIMALS; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NICOTINE; NITROSAMINES; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 81555222631     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0453     Document Type: Review

References (52)

1. Fiore MC, Jaen CR, Baker TB. Treating tobacco use and dependence: 2008 update. Agency for Healthcare Research and Quality. [monograph on the Internet]. Washington: U.S. Department of Health and Human Services; 2008. Available from: www.surgeongeneral.gov/tobacco/treating-tobacco-use08.pdf.
2. Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P, et al. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ 2009;338:b1024.
3. Robles GI, Singh-Franco D, Ghin HL. A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations. Clin Ther 2008;30:800-12. (Pubitemid 351802284)
4. Hudmon KS, Corelli RL, Prokhorov AV. Current approaches to pharmacotherapy forsmoking cessation. TherAdv Respir Dis2010;4:35-47.
5. Agboola S, McNeill A, Coleman T, Leonardi BJ. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction 2010;105:1362-80.
6. Coleman T, Agboola S, Leonardi-Bee J, Taylor M, McEwen A, McNeill A, et al. Relapse prevention in UK Stop Smoking Services: current practice, systematic reviews of effectiveness and cost-effectiveness analysis. Health Technol Assess 2010;14:1-152;iii-iv.
7. Zapawa LM, Hughes JR, Benowitz NL, Rigotti NA, Shiffman S. Cautions and warnings on the US OTC label for nicotine replacement: what's a doctor to do? Addict Behav 2011;36:327-32.
8. Murray RP, Connett JE, Zapawa LM. Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study. Nicotine Tob Res 2009;11:1076-82.
9. Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. Lancet Oncol 2008;9:667-75. (Pubitemid 351878052)
10. Boffetta P, Aagnes B, Weiderpass E, Andersen A. Smokeless tobacco use and risk of cancer of the pancreas and other organs. Int J Cancer 2005;114:992-5.
11. Luo J, Ye W, Zendehdel K, Adami J, Adami HO, Boffetta P, et al. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet 2007;369:2015-20. (Pubitemid 46899161)
12. Accortt NA, Waterbor JW, Beall C, Howard G. Cancer incidence among a cohort of smokeless tobacco users (United States). Cancer Causes Control 2005;16:1107-15. (Pubitemid 41356009)
13. Egleton RD, Brown KC, Dasgupta P. Nicotinic acetylcholine receptors in cancer: multiple roles in proliferation and inhibition of apoptosis. Trends Pharmacol Sci 2008;29:151-8.
14. Chen RJ, Ho YS, Guo HR, Wang YJ. Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta-adrenoceptors in human bladder cancer cells. Toxicol Sci 2010;115:118-30.
15. Lee HJ, Guo HY, Lee SK, Jeon BH, Jun CD, Lee SK, et al. Effects of nicotine on proliferation, cell cycle, and differentiation in immortalized and malignant oral keratinocytes. J Oral Pathol Med 2005;34:436-43.
16. Zheng Y, Ritzenthaler JD, Roman J, Han S. Nicotine stimulates human lung cancer cell growth by inducing fibronectin expression. Am J Respir Cell Mol Biol 2007 Dec;37:681-90. (Pubitemid 350211638)
17. Schuller HM. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nat Rev Cancer 2009;9:195-205.
18. Catassi A, Servent D, Paleari L, Cesario A, Russo P. Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: implications on lung carcinogenesis. Mutat Res 2008;659:221-31.
19. Dasgupta P, Chellappan SP. Nicotine-mediated cell proliferation and angiogenesis: new twists to an old story. Cell Cycle 2006;5:2324-8. (Pubitemid 44801377)
20. Chen RJ, Ho YS, Guo HR, Wang YJ. Rapid activation of Stat3 and ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells. Toxicol Sci 2008;104:283-93.
21. Dasgupta P, Kinkade R, Joshi B, Decook C, Haura E, Chellappan S, et al. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci U S A 2006;103:6332-7.
22. Onoda N, Nehmi A, Weiner D, Mujumdar S, Christen R, Los G, et al. Nicotine affects the signaling of the death pathway, reducing the response of head and neck cancer cell lines to DNA damaging agents. Head Neck 2001;23:860-70. (Pubitemid 32862290)
23. Wright SC, Zhong J, Zheng H, Larrick JW. Nicotine inhibition of apoptosis suggests a role in tumor promotion. FASEB J 1993;7:1045-51. (Pubitemid 23243447)
24. Zeidler R, Albermann K, Lang S. Nicotine and apoptosis. Apoptosis 2007;12:1927-43. (Pubitemid 47498221)
25. Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001;7:833-9. (Pubitemid 32691639)
26. Heeschen C, Weis M, Aicher A, Dimmeler S, Cooke JP. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin Invest 2002;110:527-36. (Pubitemid 34919707)
27. Doolittle DJ, Rahn CA, Lee CK. The effect of exposure to nicotine, carbon monoxide, cigarette smoke or cigarette smoke condensate on the mutagenicity of rat urine. Mutat Res 1991;260:9-18.
28. Yim SH, Hee SS. Genotoxicity of nicotine and cotinine in the bacterial luminescence test. Mutat Res 1995;335:275-83.
29. Doolittle DJ, Winegar R, Lee CK, Caldwell WS, Hayes AW, de Bethizy JD, et al. The genotoxic potential of nicotine and its major metabolites. Mutat Res 1995;344:95-102.
30. Trivedi AH, Dave BJ, Adhvaryu SG. Assessment of genotoxicity of nicotine employing in vitro mammalian test system. Cancer Lett 1990;54:89-94. (Pubitemid 20333718)
31. Trivedi AH, Dave BJ, Adhvaryu SC. Genotoxic effects of nicotine in combination with arecoline on CHO cells. Cancer Lett 1993;74:105-10. (Pubitemid 23331054)
32. Mizusaki S, Okamoto H, Akiyama A, Fukuhara Y. Relation between chemical constituents of tobacco and mutagenic activity of cigarette smoke condensate. Mutat Res 1977;48:319-25. (Pubitemid 8107644)
33. Cheng Y, Li HL, Wang HF, Sun HF, Liu YF, Peng SX, et al. Inhibition of nicotine-DNA adduct formation in mice by six dietary constituents. Food Chem Toxicol 2003;41:1045-50. (Pubitemid 36694513)
34. Stepanov I, Carmella SG, Han S, Pinto A, Strasser AA, Lerman C, et al. Evidence for endogenous formation of N0-nitrosonornicotine in some long-term nicotine patch users. Nicotine Tob Res 2009;11:99-105.
35. Hecht SS, Carmella SG, Chen M, Dor Koch JF, Miller AT, Murphy SE, et al. Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. Cancer Res 1999;59:590-6. (Pubitemid 29076055)
36. Stepanov I, Carmella SG, Briggs A, Hertsgaard L, Lindgren B, Hatsukami D, et al. Presence of the carcinogen N0-nitrosonornicotine in the urine of some users of oral nicotine replacement therapy products. Cancer Res 2009;69:8236-40.
37. Maier CR,Hollander MC, Hobbs EA, Dogan I, Dennis PA. Nicotine does not enhance tumorigenesis in mutant K-Ras-driven mouse models of lung cancer. Cancer Prev Res 2011;4:1743-51.
38. Murphy SE, von Weymarn LB, Schutten MM, Kassie F, Modiano JF. Chronic nicotine consumption does not influence 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone induced lung tumorigenesis. Cancer Prev Res 2011;4:1752-60.
39. Waldum HL, Nilsen OG, Nilsen T, Rørvik H, Syversen V, Sanvik AK, et al. Long-term effects of inhaled nicotine. Life Sci 1996;58:1339-46. (Pubitemid 26109597)
40. Martin JC, Martin DD, Radow B, Day HE. Life span and pathology in offspring following nicotine and methamphetamine exposure. Exp Aging Res 1979;5:509-22. (Pubitemid 10214809)
41. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003;3:733-44. (Pubitemid 37328812)
42. Chen YP, Squier CA. Effect of nicotine on 7,12-dimethylbenz[a]anthracene carcinogenesis in hamster cheek pouch. J Natl Cancer Inst 1990;82:861-4. (Pubitemid 20149446)
43. Gurkalo VK, Volfson NI. Nicotine influence upon the development of experimentalstomachtumors.ArchGeschwulstforsch1982;52:259-65. (Pubitemid 12043118)
44. LaVoie EJ, Shigematsu A, Rivenson A, Mu B, Hoffmann D. Evaluation of the effects of cotinine and nicotine-N′-oxides on the development of tumors in rats initiated with N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide. J Natl Cancer Inst 1985;75:1075-81. (Pubitemid 16213336)
45. Habs M, Schmahl D. Influence of nicotine on N-nitrosomethylurea-induced mammary tumors in rats. Klin Wochenschr 1984;62 Suppl 2:105-8. (Pubitemid 14075590)
46. Zeller WJ, Berger MR. Nicotine and estrogen metabolism-possible implications of smoking for growth and outcome of treatment of hormone-dependent cancer? Discussion of experimental results. J Cancer Res Clin Oncol 1989;115:601-3. (Pubitemid 20059010)
47. Al-Wadei HA, Plummer HK III, Schuller HM. Nicotine stimulates pancreatic cancer xenografts by systemic increase in stress neurotransmitters and suppression of the inhibitory neurotransmitter gamma-aminobutyric acid. Carcinogenesis 2009;30:506-11.
48. Davis R, Rizwani W, Banerjee S, Kovacs M, Haura E, Coppola D, et al. Nicotine promotes tumor growth and metastasis in mouse models of lung cancer. PLoS One 2009;4:e7524.
49. Jarzynka MJ, Guo P, Bar-Joseph I, Hu B, Cheng SY. Estradiol and nicotine exposure enhances A549 bronchioloalveolar carcinoma xenograft growth in mice through the stimulation of angiogenesis. Int J Oncol 2006;28:337-44.
50. Apelberg BJ, Onicescu G, vila-Tang E, Samet JM. Estimating the risks and benefits of nicotine replacement therapy for smoking cessation in the United States. Am J Public Health 2010;100:341-8.
51. Temple R. Cancer chemoprevention - the cardiovascular model. Cancer Prev Res 2011;4:307-10.
52. Meyskens FL, Curt GA, Brenner DE, Gordon G, Herberman RB, Finn O, et al. Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prev Res 2011;4:311-23.